MedTrace Logo

Hypofractionated Proton Radiation Therapy for Low and Intermediate Risk Prostate Cancer

NCT01368055 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 361

Last updated 2025-08-29

No results posted yet for this study

Summary

The purpose of this trial is to give a shorter course (5 ½-6 weeks) of proton radiation that has as little side effects on normal bladder and rectal tissues as the usual longer course (8 weeks) of proton radiation, without decreasing the chance of killing prostate cancer cells.

Conditions

Interventions

RADIATION

70 Gy/CGE

Low Risk

RADIATION

72.5 Gy/CGE

Intermediate Risk

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Curtis Bryant, MD, MPH · University of Florida Proton Therapy Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2025-08-31
Completion
2025-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01368055 on ClinicalTrials.gov